Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025 Both parties strengthening focus on antibiotic stewardship and planning to engage…
Entries by https://www.sandoz.com/rss/feeds/news/media-releases.xml
Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025 Both parties strengthening focus on antibiotic stewardship and planning to engage…
Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex genericsRespiratory diseases are leading cause of death and disability and impose huge financial b…
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines1,4Cost savings from Lenalidomide Sandoz can expand treatment options for patients with haemato-oncology conditions1,2Sandoz is comm…
Ad hoc announcement pursuant to Art. 53 LRQ4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD)IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12% USD)Sandoz sales grew +2% (cc, 0% USD) and core operati…
Ad hoc announcement pursuant to Art. 53 LRQ4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD)IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12% USD)Sandoz sales grew +2% (cc, 0% USD) and core operati…
Submission is supported by comprehensive package of analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc. Breast cancer is one of most common types of cancer in women, accounting for over 355,000 new ca…
Biologics License Application (BLA) is supported by analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc. Trastuzumab is monoclonal antibody used to treat human epidermal growth factor receptor 2 posi…
Ad hoc announcement pursuant to Art. 53 LRQ3 net sales grew +5% (cc¹, +6% USD)Innovative Medicines grew +7% (cc, +8% USD)Strong performance of key growth drivers: Entresto (+44% cc), Cosentyx (+22% cc), Kesimpta (USD 109 million), Jakavi (+26% cc), Zol…
At least 24 million doses of the mRNA-based vaccine will be filled in 2022 into vials under sterile conditions at Novartis Technical Operations state-of-the-art facility in Ljubljana, SloveniaNew agreement follows earlier supply agreement for the fill …